• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » May 2012 – The CenterWatch Monthly : PDF
May 2012 – The CenterWatch Monthly : PDF

May 2012 – The CenterWatch Monthly : PDF

$79.00

Product Details

Newer sites most optimistic about the future

Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns about the stability of the clinical research environment. The size of an individual grant for industry sponsored trials has either declined or remained flat for sites of all sizes and types, and a majority of sites in all subgroups, except for those in the largest and least experienced segments, won’t hire new staff this year…

Risk-based monitoring slow to catch on with industry

It’s estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of study budgets. Now, posited the FDA and European Medicines Agency (EMA), the industry has the technology to handle most monitoring centrally. Thus, risk-based monitoring could save the industry millions in monitoring costs. But so far the sponsor community—slow to change and also fearing the regulatory bodies may not truly mean what they say—is not leaping to adopt the new concept…

Eye On: Millennium

Millennium, The Takeda Oncology Company, is a biopharmaceutical genomics company focused exclusively on oncology. Millennium discovers and develops novel treatments, applying world-class recombinant technology to a wide variety of oncology disease targets. The company’s largest commercial success to date has been Velcade (bortezomib), developed through Nobel Prize-winning protein homeostasis science and now approved in more than 87 countries for multiple myeloma and relapsed mantle cell lymphoma…

  • Taking a chance on research naïve staff
  • The changing trend for REMS 2012
  • Regulatory Update
  • Month in Review
  • CRO Industry Update
  • Grant Lead Opportunities
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing